JP2015518007A - スケドスポリウム属感染症の治療方法 - Google Patents

スケドスポリウム属感染症の治療方法 Download PDF

Info

Publication number
JP2015518007A
JP2015518007A JP2015514283A JP2015514283A JP2015518007A JP 2015518007 A JP2015518007 A JP 2015518007A JP 2015514283 A JP2015514283 A JP 2015514283A JP 2015514283 A JP2015514283 A JP 2015514283A JP 2015518007 A JP2015518007 A JP 2015518007A
Authority
JP
Japan
Prior art keywords
acyl
compound
alkyl
acid
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518007A5 (enExample
Inventor
ジュリー、フィリップス
タニア、ソレル
シャロン、チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biodiem Ltd
Original Assignee
Biodiem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902243A external-priority patent/AU2012902243A0/en
Application filed by Biodiem Ltd filed Critical Biodiem Ltd
Publication of JP2015518007A publication Critical patent/JP2015518007A/ja
Publication of JP2015518007A5 publication Critical patent/JP2015518007A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015514283A 2012-05-30 2013-05-13 スケドスポリウム属感染症の治療方法 Pending JP2015518007A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902243 2012-05-30
AU2012902243A AU2012902243A0 (en) 2012-05-30 Method of treating Seedosporium spp. infection
PCT/AU2013/000487 WO2013177608A1 (en) 2012-05-30 2013-05-13 Method of treating scedosporium spp. infection

Publications (2)

Publication Number Publication Date
JP2015518007A true JP2015518007A (ja) 2015-06-25
JP2015518007A5 JP2015518007A5 (enExample) 2016-06-30

Family

ID=49672167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514283A Pending JP2015518007A (ja) 2012-05-30 2013-05-13 スケドスポリウム属感染症の治療方法

Country Status (9)

Country Link
US (1) US9867802B2 (enExample)
EP (1) EP2854799B1 (enExample)
JP (1) JP2015518007A (enExample)
CN (1) CN104519882A (enExample)
AU (2) AU2013204604B2 (enExample)
CA (1) CA2874881A1 (enExample)
SG (1) SG11201407924RA (enExample)
WO (1) WO2013177608A1 (enExample)
ZA (1) ZA201408975B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023741A1 (en) * 2017-08-01 2019-02-07 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCUS AND ENTEROCOCCUS INFECTIONS USING SUBSTITUTED NITROSTYRENE COMPOUNDS
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985761A (en) * 1974-10-24 1976-10-12 Sarabhai Research Centre Nitrothiazolyl derivatives of nitrostyrene
JPS5535017A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Factory Inc Beta-nitrostyrene derivative
JP2005511487A (ja) * 2001-06-18 2005-04-28 バイオディエム リミティッド 抗微生物及び放射線防御化合物
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
JP2009512729A (ja) * 2005-10-24 2009-03-26 スタヴァル ファーマ リミテッド 菌類及び細菌を処理、抑制、殺滅する方法
JP2011518844A (ja) * 2008-04-25 2011-06-30 ナノバイオ コーポレーション 真菌、酵母および糸状菌感染症を治療するためのナノエマルション
WO2011154298A1 (en) * 2010-06-07 2011-12-15 Janssen Pharmaceutica Nv NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220103A1 (en) * 2005-10-24 2008-09-11 Jay Birnbaum Method for treating/controlling/killing fungi and bacteria on living animals

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985761A (en) * 1974-10-24 1976-10-12 Sarabhai Research Centre Nitrothiazolyl derivatives of nitrostyrene
JPS5535017A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Factory Inc Beta-nitrostyrene derivative
JP2005511487A (ja) * 2001-06-18 2005-04-28 バイオディエム リミティッド 抗微生物及び放射線防御化合物
JP2009512729A (ja) * 2005-10-24 2009-03-26 スタヴァル ファーマ リミテッド 菌類及び細菌を処理、抑制、殺滅する方法
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
JP2011518844A (ja) * 2008-04-25 2011-06-30 ナノバイオ コーポレーション 真菌、酵母および糸状菌感染症を治療するためのナノエマルション
WO2011154298A1 (en) * 2010-06-07 2011-12-15 Janssen Pharmaceutica Nv NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
APPL. SCI., 2011.02.23, VOL.2, P.114-128, JPN6017010020, ISSN: 0003524241 *
惟村光宣, 高峰研究所年報, vol. 13, JPN6009010398, 1961, pages 212 - 215, ISSN: 0003524242 *

Also Published As

Publication number Publication date
US20150126436A1 (en) 2015-05-07
AU2013204604B2 (en) 2016-05-19
CN104519882A (zh) 2015-04-15
ZA201408975B (en) 2016-10-26
US9867802B2 (en) 2018-01-16
EP2854799B1 (en) 2018-04-25
HK1209052A1 (en) 2016-03-24
CA2874881A1 (en) 2013-12-05
SG11201407924RA (en) 2014-12-30
AU2013270430A1 (en) 2014-12-18
EP2854799A4 (en) 2015-10-21
AU2013204604A1 (en) 2013-12-19
WO2013177608A1 (en) 2013-12-05
EP2854799A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
JP2015518007A (ja) スケドスポリウム属感染症の治療方法
ES2437346T3 (es) Procedimiento para la producción de derivado de diamina
AU2014323822B2 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
EP3943495A1 (en) Small molecule modulators of il-17
JPS62212322A (ja) 医薬組成物および処置法
US20230029009A1 (en) Chemical compounds
JP2004501901A (ja) イミノピリミジン系ｎｍｄａｎｒ２ｂ受容体拮抗薬
CN1863788B (zh) 抗菌和防辐射化合物
US10570144B2 (en) Substituted ureas as prostaglandin EP4 receptor antagonists
BRPI0810192B1 (pt) aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo.
US20240374573A1 (en) Imidazole containing compounds, derivatives therefore, and uses thereof
JPH10316563A (ja) 原生動物感染の治療方法
CN107400126A (zh) 新型噁唑烷酮类化合物及其制备方法和在医学上的应用
AU2024263053A1 (en) Imidazole containing compounds, derivatives therefore, and uses thereof
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
EA011024B1 (ru) Антигельминтные производные имидазола и тиазола
US20230122967A1 (en) Novel compounds as inhibitors of pcsk9
JP3070812B2 (ja) 新規オキサゾリジン
JP5714602B2 (ja) 新規な２−アルキニル−ｎ９−プロパギルアデニンおよびその医薬用途
CN111499623B (zh) 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
HK1209052B (en) 3,4-methylenedioxy-beta-methyl-beta-nitrostyrene for use in the treatment of scedosporium spp. infection
JP2023542455A (ja) ３－デオキシ－２－ケトアルドン酸窒素含有誘導体、その製造方法及びその使用
CN117105868A (zh) 酰胺类醛脱氢酶激动剂、其合成方法及用途
CN120441533A (zh) 地氯雷他定衍生物及其在制备用于周围神经病变药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171205